PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT by L. Frölich, V. Blumenberg, K. Rejeski, C. Schmidt, M. Winkelmann, F. Schöberl, L. von Baumgarten, W. Kunz, V. Bücklein, M. Subklewe

Get full text

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE by V. Blumenberg, L. Siegmund, L. Frölich, K. Rejeski, M. Warm, F. Hildebrand, C. Schmidt, M. von Bergwelt, V. Bücklein, M. Subklewe

Get full text

P1438: PROCALCITONIN IS ELEVATED IN SEVERE INFECTIONS AFTER CD19 CAR-T IN R/R B-NHL AND ENABLES DISCRIMINATION OF EARLY INFECTIONS FROM CRS – PARTICULARLY IN COMBINATION WITH THE C... by K. Rejeski, V. Blumenberg, F. Hildebrand, L. Frölich, P. Karschnia, M. Dreyling, M. von Bergwelt-Baildon, C. Schmidt, M. Subklewe, V. Bücklein

Get full text

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CH... by V. Bücklein, A. Perez, G. Iacoboni, K. Rejeski, U. Holtick, O. Penack, S. Kharboutli, V. Blumenberg, J. Ackermann, L. Frölich, G. Johnson, K. Patel, B. Arciola, C. Schmidt, O. Albanyan, P. Gödel, E. Hoster, L. Bullinger, A. Mackensen, F. Locke, M. von Bergwelt, P. Barba, M. D. Jain, M. Subklewe

Get full text